Table 2.
Incidence of the combined primary end point and of each of its various components, and all-cause death during the DIABHYCAR trial according to the ACE insertion/deletion polymorphism
| Study end point | All patients |
ACE genotype
|
P value (log-rank): II vs. ID vs. DD | ||
|---|---|---|---|---|---|
| ACE II | ACE ID | ACE DD | |||
| n enrolled | 3,126 | 549 | 1,463 | 1,114 | |
| Primary combined end point | 495/3.78 (3.45–4.10) | 97/4.20 (3.38–5.02) | 230/3.76 (3.28–4.23) | 168/3.60 (3.06–4.23) | 0.489 |
| Cardiovascular death | 208/1.52 (1.31–1.72) | 48/1.99 (1.43–2.55) | 84/1.30 (1.02–1.58) | 76/1.56 (1.22–1.91) | 0.060 |
| Myocardial infarction (fatal and nonfatal) | 95/0.69 (0.55–0.83) | 18/0.74 (0.40–1.09) | 49/0.76 (0.55–0.97) | 28/0.58 (0.36–0.79) | 0.493 |
| Stroke (fatal and nonfatal) | 157/1.17 (0.98–1.35) | 32/1.36 (0.89–1.82) | 73/1.15 (0.89–1.42) | 52/1.09 (0.79–1.38) | 0.615 |
| Heart failure requiring hospitalization | 136/1.00 (0.84–1.17) | 21/0.89 (0.51–1.27) | 67/1.06 (0.80–1.31) | 48/0.99 (0.71–1.26) | 0.769 |
| ESRF | 18/0.13 (0.07–0.19) | 7/0.29 (0.07–0.51) | 8/0.12 (0.04–0.21) | 3/0.06 (0.01–0.13) | 0.034 |
| Death (all-cause) | 455/3.13 (3.01–3.61) | 88/3.68 (2.92–4.43) | 191/2.95 (2.53–3.36) | 176/3.61 (3.09–4.14) | 0.071 |
Data are expressed as n or number of events per 100 patient-years (95% CI). Primary combined end point: time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, nonfatal heart failure requiring hospitalization, or ESRF.